Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
NCT04145349Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2020
- Primary completion
- Jun 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of ramucirumab in desmoplastic small round cell tumor (DSRCT), sponsored by Eli Lilly and Company. Started Jan 2020; status: completed.
02
Drugs
ramucirumab
03
Conditions
desmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NCT04145349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04145349.